Duloxetine compared with fluoxetine and venlafaxine: Use of meta-regression analysis for indirect comparisons

BMC Psychiatry

Volumn 6, Issue , 2006, Pages

  Eckert, Laurent ^a,b   Lançon, Christophe ^c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Hôpital Sainte Marquerite   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYL 1 [(1,2,3,4 TETRAHYDRO 5,6 METHYLENEDIOXY 1 NAPHTHYL)METHYL]PYRROLIDINE; AMFEBUTAMONE; DULOXETINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; MIANSERIN; OLANZAPINE; PLACEBO; RISPERIDONE; TRAZODONE; VENLAFAXINE;

CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EFFECT SIZE; EMBASE; HUMAN; INFORMATION RETRIEVAL; MAJOR DEPRESSION; MEDLINE; METHODOLOGY; OUTCOME ASSESSMENT; PUBLICATION; REGRESSION ANALYSIS; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; FLUOXETINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; THIOPHENES; TREATMENT OUTCOME;

EID: 33747662960     PISSN: 1471244X     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-6-30     Document Type: Review

References (55)

1. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW: LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 1993, 8:23-33.
2. Pitsikas N: Duloxetine. Curr Opin Investig Drugs 2000, 1:116-121.
3. Falissard B, Lothgren M, Perahia D, Garcia-Cebrian A: Meta-analyses of duloxetine in the treatment of MDD [Poster]. presented at the 4th International Forum on Mood and Anxiety Disorders: abstract PO 13, 19 Nov 2003 2003.
4. Greist J, McNamara RK, Mallinckrodt CH, Rayamajhi JN, Raskin J: Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 2004, 26:1446-1455.
5. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF: Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005, 39:43-53.
6. EMEA: European Public Assessment: Report. Scientific discussion. Cymbalta. 2005.
7. EMEA, CPMP (Comittee for Proprietary Medicinal Products. Concept Paper on the revision of the Committee for Proprietary Medicinal Products): Note for guidance on medicinal products for the treatment of depression. CPMP/EWP/518/97 2002.
8. Edwardes MD, Baltzan M: The generalization of the odds ratio, risk ratio and risk difference to r x k tables. Statistics in Medicine 2000, 19:1901-1914.
9. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, Bradburn M, Eastwood AJ: Indirect comparisons of competing interventions. Health Technology Assessment 2005, 9(26):.
10. Van Houwelingen HC, Arends LR, Stijnen T: Advanced methods in meta-analysis: multivariate approach and meta-regression. Statistics in medicine 2002, 21:589-624.
11. Andorn AC, Mallinckrodt C, Watkin J, Wohlreich M: Efficacy of duloxetine in patients with mild, moderate, or severe depressive symptoms. [Poster]. presented at the 158th Annual Meeting of the American Psychiatric Association. Abstract NR363, 24 May 2005 2005, 135:.
12. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA: Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002, 63:225-231.
13. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA: Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002, 63:308-315.
14. SAS Institute Inc. 100 SAS Campus Drive, Cary, NC 27513-2414 USA.
15. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA: Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002, 36:383-390.
16. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I: Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004, 14:457-470.
17. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA: Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004. 24.389-399.
18. Fabre LF, Crismon L: Efficacy of fluoxetine in outpatients with major depression. Curr Ther Res 1985, 37:115-123.
19. Stark P, Hardison CD: A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985, 46:53-58.
20. Cohn JB, Wilcox C: A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 1985, 46:26-31.
21. Fieve RR, Goodnick PJ, Peselow E, Schlegel A: Fluoxetine response: endpoint vs pattern analysis. Int Clin Psychopharmacol 1986, 1:320-323.
22. Rickels K, Amsterdam JD, Avallone MF: Fluoxetine in major depression: a controlled study. Curr Ther Res 1986, 39:559-563.
23. Goodnick PJ, Fieve RR, Peselow ED, Barouche F, Schlegel A: Double-blind treatment of major depression with fluoxetine: use of pattern analysis and relation of HAM-D score to CGI change. Pyschopharmacol Bull 1987, 23:162-163.
24. Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL: Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 1987, 23:164-168.
25. Fabre LF, Putman HP III: A fixed-dose clinical trial of fluoxetine in outpatients with major depression. J Clin Psychiatry 1987, 48:406-408.
26. Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M: Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 1988, 24:183-188.
27. Harto NE, Spera KF, Branconnier RJ: Fluoxetine-induced reduction of body mass in patients with major depressive disorder. Psychopharmacol Bull 1988, 24:220-223.
28. Byerley WF, Reimherr FW, Wood DR, Grosser BI: Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. J Clin Psychopharmacol 1988, 8:112-115.
29. Muijen M. Roy D, Silverstone T, Mehmet A, Christie M: A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatr Scand 1988, 78:384-390.
30. Feighner JP, Boyer WF, Merideth CH, Hendrickson GG: A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression. Int Clin Psychopharmacol 1989, 4:127-134.
31. Dunlop SR, Dornseif BE, Wernicke JF, Potvin JH: Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol Bull 1990, 26:173-180.
32. Valducci M, Valducci A, Paoletti C, Colonna CV: A double-blind, placebo controlled clinical trial to evaluate efficacy and safety of fluoxetine in the treatment of major depression. G Ital Ric Clin Ther 1992, 13:59-64.
33. Heiligenstein JH, Tollefson GD, Faries DE: Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo. J Affect Disord 1994, 30:163-173.
34. Sramekh JJ, Kashkin K, Jasinsky O, Kardatzke D, Kennedy S, Cutler NR: Placebo-controlled study of a BT-200 versus fluoxetine in the treatment of major depressive disorder. Depression 1995, 3:199-203.
35. Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL: A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 1998, 10:145-150.
36. Rudolph RL, Feiger AD: A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999, 56:171-181.
37. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL: Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000, 11:58-65.
38. Coleman CC, King BR, Bolden-Watson C, Book MJ, Segraves RT, Richard N, Ascher J, Batey S, Jamerson B, Metz A: A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001. 23:1040-1058.
39. Khan A, Fabre LF, Rudolph R: Venlafaxine in depressed outpatients. Psychopharmacol Bull 1991, 27:141-144.
40. Schweizer E, Weise C, Clary C, Fox I, Rickels K: Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991, 11:233-236.
41. Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E: A comparison of venlafaxine, trazodone, and placebo in major depression [published erratum appears in J Clin Psychopharmacol 1994 Aug;14(4):292]. J Clin Psychopharmacol 1994, 14:99-106.
42. Schweizer E, Feighner J, Mandos LA, Rickels K: Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994, 55:104-108.
43. Cunningham LA: Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatry 1997, 9:157-164.
44. Thase ME: Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry 1997, 58:393-398.
45. Silverstone PH, Ravindran A: Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999, 60:22-28.
46. Sauriol L, Laporta M, Edwardes MD, Deslandes M, Ricard N, Suissa S: Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach. Clin Ther 2001, 23:942-956.
47. Song F, Altman DG, Glenny AM, Deeks JJ: Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003, 326:472.
48. Vis PMJ, van Baardewijk M, Einarson TR: Duloxetine and venlafaxine-XR in the treatment of MDD: a meta-analysis of randomized clinical trials. Ann Pharmacother 2005, 39(11):1798-807.
49. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS: Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005, 143:415-426.
50. Bech P, Ciadella P, Haugh MC, Birkett MA, Hours A, Boissel JP, Tollefson GD: Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. British Journal of Psychiatry 2000, 176:421-428.
51. Greenberg RP, Bornstein RF, Zborowski MJ, Fisher S, Greenberg MD: A meta-analysis of fluoxetine outcome in the Treatment of depression. The journal of Nervous and Mental Disease 1994, 18(10):547-551.
52. Song F, Glenny AM, Altman DG: Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery. Control Clin Trials 2000, 21:488-497.
53. McAlister FA, Laupacis A, Wells GA, Sackett DL: Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999, 282:1371-1377.
54. Egger M, Davey SG, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
55. Geddes J. Freemantle N. Harrison P, Bebbington P: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000, 321:1371-1376.